Soft Mist technology: where the limit of applicability lies

A project where belief in a “universal swappable nozzle” cost the client roughly $120,000 — and how an engineering review stopped further spend. The physics of atomization confines soft-mist to low-viscosity aqueous solutions for local delivery to the bronchi and lungs; freely swapping actives for viscous formulations in the existing design is not possible. The client and project details are not disclosed under NDA.

How our process works Message on Telegram

1. The client's initial belief

A soft-mist inhaler is a propellant-free, spring-driven device. The spring forces liquid through a capillary into a silicone nozzle (Uniblock) with two micro-channels about 5–8 µm across; the two jets collide and shatter the solution into a slow aerosol cloud. Each actuation meters roughly 11.5–15 µL of solution and forms an aerosol with a typical aerodynamic diameter of 2–3 µm.

The client's hypothesis

The nozzle and cartridge are separate from the body — so “fill the cartridge with a different substance and you get a new product on the same platform.” On that basis they ran a multi-year in-house nozzle development, assuming atomization would stay acceptable across a wide range of actives, including more viscous and concentrated solutions.

2. What the engineering analysis showed

Soft mist works on one narrow physical condition — low liquid viscosity. Flow through the micro-channel follows the Hagen–Poiseuille law: at fixed pressure and geometry, flow is inversely proportional to viscosity (Q ∝ 1/µ), and doubling the viscosity halves the flow. The atomization pressure is set by the spring's stored energy (about 220 atm) and can't be raised at will — a pressurized cartridge is unacceptable on safety grounds. Hence a hard viscosity ceiling of about 2 cP (typical working value ~1.5 cP): beyond it the device stops working in its design regime. This isn't a matter of tuning but a consequence of the fixed-pressure / fixed-nozzle-geometry pairing. How rising viscosity hits the device:

Parameter	Low viscosity (≤~1.5 cP)	High viscosity (>~2 cP)	Cause
Flow through the nozzle	As designed	Drops (Q ∝ 1/µ)	Hagen–Poiseuille law
Jet break-up into aerosol	Complete, MMAD 2–3 µm	Incomplete, larger droplets	Insufficient Weber number at reduced velocity
Plume height (reach)	Nominal	Reduced	Lower jet velocity and momentum
Spray duration	~1.2–1.5 s	Rises (>3 s)	Reduced flow at the same dose volume
Lung delivery efficiency	Deposition 37–53%	Falls	Large droplets settle in the oropharynx, not reaching the lungs

3. The negative result: the technology's boundaries

The review led to a negative but clear conclusion. Soft mist is not a universal carrier. It works only where two conditions hold at once: the solution is low-viscosity and aqueous, and the therapeutic target is local, in the airways and lungs.

Every new active is not a “cartridge swap” but a separate formulation and engineering task.
Either the solution is tuned to the device's viscosity corridor, or the device is re-engineered (a stiffer spring, a different capillary bore, a larger plunger area) — either of which takes the project outside the original “universal swappable nozzle” idea.

The headline conclusion

Soft Mist fits local delivery to the bronchi and lungs — above all COPD therapy and bronchial directions (local antibiotics, inhaled corticosteroids). High-viscosity solutions can't be used: beyond ~2 cP the inhaler's efficiency falls, plume height shrinks and spray duration grows. Freely swapping the active “under the same nozzle” for arbitrary, viscous or complex formulations in the existing design is not possible.

4. Why this is a result, not a failure

The client spent on the order of $120,000 developing a nozzle around a hypothesis that didn't survive an engineering review. The temptation is to call it a failure. In fact the negative result, obtained in 2026, stopped far larger spend: scaling nozzle production, formulation cycles for viscous substances, regulatory preparation of a product that wouldn't have worked in the device.

The value of de-risking

A mistaken premise is exposed by calculation in weeks, not by a production batch over years. The project was refocused from a “universal platform” to a realistic corridor of use — low-viscosity aqueous solutions for local lung therapy, where the technology is genuinely strong.

5. Caveats and data status

The device figures (pressure ~220 atm, dose 11.5–15 µL, MMAD 2–3 µm, deposition 37–53%, channel bore 5–8 µm) are reference values from the soft-mist platform literature, confirmed by an independent source check; they were not measured on the client's specific device. The viscosity limit of about 2 cP is an engineering estimate from the pressure–geometry–flow relationship, not the result of bench tests of this particular nozzle. The spend (~$120,000) is stated by the client. The client and project details are not disclosed under a confidentiality agreement.

Need engineering de-risking for your technology?

Message on Telegram — we'll test the key engineering premise of your device or formulation by calculation, before years and production batches go into it.

Message on Telegram · @pmatveyeu

Need engineering de-risking for your technology?

Message on Telegram — we'll test the key engineering premise of your device or formulation by calculation, before years and production batches go into it.

Contact: Telegram @pmatveyeu · +375 44 509-04-01 · gxplaunch.com

Technical statements are based on an audited engineering / pharmacokinetic assessment of the soft-mist platform (gxplaunch internal report, 2026): deposition 37–53% vs ~21% for pMDI — Brand et al., Int J COPD, 2008, PMID 19281091; nozzle geometry — Dalby et al., 2011, PMID 22915941. This material is informational and describes an engineering de-risking case; it is not medical advice, a regulatory opinion, or investment advice. The technical conclusions concern the soft-mist platform in general; applying them to a specific device or product requires separate engineering and clinical verification.